Ventyx Biosciences Inc ( VTYX ) stock is trading lower on Monday.

The company released results from the Phase 2 trial of allosteric TYK2 inhibitor VTX958 in participants with moderately to severely active Crohn’s disease, a type of inflammatory bowel disease that irritates and causes swelling in digestive tract.

The Phase 2 trial enrolled 109 participants randomized to one of two VTX958 doses (225 mg and 300 mg twice daily) or placebo for a 12-week induction treatment period, followed by a long-term extension period.

The primary endpoint was the change in the mean Crohn’s disease activity index (CDAI) score (a patient-reported outcome that determines the current severity of Crohn’s disease) from baseline to Week 12.

A key secondary endpoint in this trial was the endoscopic response, defined as a 50% reduction in the simple endoscopic score for Crohn’s disease (SES-CD).

The trial did not meet its primary endpoint of change in mean CDAI score due to a higher-than-anticipated placebo response.

A dose-dependent treatment effect was observed on the key secondary endpoint of endoscopic response at 225 mg and 300 mg doses (nominal p-value